ELDN Stock Summary and Trading Ideas (Eledon Pharmaceuticals | NASDAQ:ELDN)

Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.

Eledon Pharmaceuticals trades on the NASDAQ stock market under the symbol ELDN.

As of October 28, 2026, ELDN stock price climbed to $2.76 with 1,972,574 million shares trading.

ELDN has a beta of 3.39, meaning it tends to be more sensitive to market movements. ELDN has a correlation of 0.17 to the broad based SPY ETF.

ELDN has a market cap of $224.28 million. This is considered a Small Cap stock.

In the last 3 years, ELDN traded as high as $5.54 and as low as $1.07.

The top ETF exchange traded funds that ELDN belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.

ELDN has underperformed the market in the last year with a return of -27.9%, while the SPY ETF gained +13.8%. In the last 3 month period, ELDN fell short of the market, returning -22.7%, while SPY returned +4.8%. However, in the most recent 2 weeks ELDN has outperformed the stock market by returning +17.9%, while SPY returned -0.7%.

ELDN support price is $2.31 and resistance is $2.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ELDN shares will trade within this expected range on the day.